Print   

Tuesday 31 March, 2009

Avacta Group plc

Analyst Presentation


                               Avacta Group plc                                

                             Analyst Presentation                              

Avacta Group plc ("Avacta" or the "Company"), which is providing innovative,
high value technologies and services to the pharmaceutical and diagnostics
markets, announces an analyst presentation to showcase the Company's
technology. The presentation will be held at 10:30am on 23 April at a location
in the City of London.

Those wishing to attend are asked to contact Kathy Boate at Haggie Financial
LLP.

                                                                  31 March 2009

Enquiries:

Haggie Financial LLP                    Tel: 020 7417 8989                     
                                                                               
Nicholas Nelson/Kathy Boate             Kathy.boate@haggie.co.uk               
                                                                               
Nominated Advisor:                      Tel: 020 7776 6550                     
                                                                               
Daniel Stewart & Company plc                                                   
                                                                               
Lindsay Mair/Charlotte Stranner                                                
                                                                               
www.danielstewart.co.uk                                                        
                                                                               
Novum Securities Limited                Tel: 020 7562 4700                     
                                                                               
Henry Turcan                                                                   

Notes to Editors:

About Avacta:

Avacta was spun-out from the University of Leeds in 2004 by its current
management team as a biophysics company, with the aim of combining the
disciplines of physics and biology to develop innovative technologies and
expert technical services to address needs in the pharmaceutical, defence and
clinical diagnostics markets.

Avacta has a core bio-analytical technology development programme addressing
the needs of the biopharmaceutical sector to fully characterise their new
products at the earliest stage in their development to reduce the risk of late
stage failure. High value solutions in clinical diagnostics are also being
targeted for these core bio-analytical technologies and for Avacta's trace gas
analysis technology as well as opportunities in industrial and military sensing
applications.

A successful and growing part of the Avacta business model is its technical
services arm, Avacta Analytical Limited, which is focused on providing leading
edge contract research to the biopharmaceutical and healthcare/personal-care
materials sectors. Avacta joined AIM in August 2006.



Investegate takes no responsibility for the accuracy of the information within the site.


The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site.



Investegate      © 2012 FE. All rights reserved.